This is a working overview of peptide mapping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
The BNP test is used as an aid in the diagnosis and assessment of severity of heart failure. A recent meta-analysis concerning effects of BNP testing on clinical outcomes of patients presenting to the emergency department with acute dyspnea revealed that BNP testing led to a decrease in admission rates and decrease in mean length of stay, although neither was statistically significant. Effects on all cause hospital mortality was inconclusive. The BNP test is also used for the risk stratification of patients with acute coronary syndromes.
=== Prescription trends === Between 1998 and 2017, along with imipramine, amitriptyline was the most commonly prescribed first antidepressant for children aged 5–11 years in England. It was also the most prescribed antidepressant (along with fluoxetine) for 12- to 17-year-olds.
=== Economics === In December 2019, the US FDA approved a generic version of apixaban produced jointly by Mylan and Micro Labs. BMS and Pfizer worked quickly to block generics from being created, and in August 2020, they won a patent infringement lawsuit against Sigmapharm, Sunshine Lake, and Unichem, after previously settling patent cases against 25 other companies. In September 2021, a Federal Circuit Court upheld the ruling. The result is that apixaban generics will most likely not be available in the United States until at least 2026, but possibly 2031. In July 2022, the Canadian generic drug company, Apotex Inc., obtained approval for marketing of apixaban. Pfizer reported revenue of US$6.747 billion for Eliquis in 2023. Apixaban is one of ten medications covered by price negotiations in the US under the Inflation Reduction Act. The negotiations, conducted by the Centers for Medicare & Medicaid Services, apply to pricing for Medicare recipients. The results of the negotiations were announced in August 2024, and Medicare's negotiated price for a 30-day supply of Eliquis is $231, a 56% decrease from the 2023 list price of $521. The pricing is set to take effect in 2026.
The most common applications are as an ingredient in dietary supplement, in cosmetics, as flavoring for foods, such as turmeric-flavored beverages in South and Southeast Asia, and as coloring for foods, such as curry powders, mustards, butters, and cheeses. As a food additive for orange-yellow coloring in prepared foods, its E number is E 100 in the European Union. It is also approved by the U.S. FDA to be used as a food coloring in US.
Bacteroides species Salmonella and Shigella Yersinia tends to be incubated at 30 °C (86 °F), which is cooler than usual Campylobacter incubated at 42 °C (108 °F), in a special environment Aeromonas Candida if the person is immunosuppressed (e.g., undergoing cancer treatment) E. coli O157 if blood is visible in the stool sample Cryptosporidium Entamoeba histolytica Intestinal parasites and their ova (eggs) can sometimes be visible to the naked eye.
Sources: en.wikipedia.org
==== Elimination ==== Tiagabine is excreted about 2% unchanged. About 25% is excreted in urine and 63% is excreted in feces. The elimination half-life of tiagabine is 4.5 to 9.0 hours. The half-life of tiagabine was found to be decreased by 50 to 65% to 3.8 to 4.9 hours (range 2–5 hours) in patients whose hepatic enzymes had been induced with other anticonvulsants including carbamazepine, phenytoin, primidone, and phenobarbital. In addition, the half-life of tiagabine is extended to 11.7 to 15.9 hours in hepatic dysfunction. These settings as such may require dose adjustment.
Concerns regarding the impact of vaccination in pregnancy, compounded through miss information disseminated through numerous sources including social media platforms, led to poor uptake in this group, despite evidence COVID-19 vaccination has no detrimental impact on live birth or miscarriage.
Regarding the positive roles of film in education, a case study analyzing students in medical fields found that the appropriate use of movies can provide helpful ideas in applying practical skills related to the medical fields, such as medical ethics, doctor-patient relationships, and mental illness. Celebrity Disclosures Celebrities' influences and their own personal experiences with mental illness can help in decreasing the stereotypes and stigma surrounding mental illness. Stars, including Lady Gaga, Serena Williams, Adele, and Dwayne Johnson, have recently disclosed their mental health journeys. Celebrities disclosing their personal experiences can help inform the public about symptoms and services regarding mental health, allowing mental health struggles to feel more normal and accepted. According to the social learning theory, people often adopt behaviors by observing others, especially celebrities, and seeing the outcomes of their actions. When a celebrity reveals their mental health struggles and remains successful and respected, it can help reduce the fear of facing negative consequences for sharing personal experiences.
=== Carbon-Carbon Composite for Hip Joint Implant === The main properties required from an artificial joint implant are long term strength and stability under cyclic load (up to seven times body weight), bio-chemical inertness, wear resistance and biological bio-compatibility. Years of clinical experience with a variety of metals and polymers fell short of achieving all the requirements. Carbon is the basic component of organic material and in certain configurations is extremely stable mechanically and chemically. In this pioneer collaboration between Rafael industry and scientists from the Technion, a carbon composite hip implant was constructed. The implant was created using carbon fibers and carbon matrix. The result achieved three dimensions stability in compression and tension. The composite hip was implanted in animal experiments at the Technion laboratory by a team of the Center for Implant Surgery. These experiments did, however, uncover the one disadvantage of carbon composite: weakness in resistance to wear in friction and cyclic motion.
Sources: en.wikipedia.org
Increased risk of developing knee and hip osteoarthritis was found among those who work with manual handling (e.g., lifting), have physically demanding work, walk at work, and have climbing tasks at work (e.g., climb stairs or ladders). With hip osteoarthritis, in particular, increased risk of development over time was found among those who work in bent or twisted positions. For knee osteoarthritis, in particular, increased risk was found among those who work in a kneeling or squatting position, experience heavy lifting in combination with a kneeling or squatting posture, and work standing up. Women and men have similar occupational risks for the development of osteoarthritis.
=== History === Cornish-Bowden, Athel (1997). New Beer in an Old Bottle. Eduard Buchner and the Growth of Biochemical Knowledge. Valencia: Universitat de Valencia. ISBN 978-84-370-3328-0. Archived from the original on 13 December 2010. Retrieved 8 December 2007., A history of early enzymology. Williams, Henry Smith (1904). Modern Development of the Chemical and Biological Sciences. A History of Science: in Five Volumes. Vol. IV. New York: Harper and Brothers. Archived from the original on 9 May 2012. Retrieved 8 December 2007., a textbook from the 19th century.
=== Creatinine clearance CCr === One method of determining GFR from creatinine is to collect urine (usually for 24 h) to determine the amount of creatinine that was removed from the blood over a given time interval. If one removes 1440 mg in 24 h, this is equivalent to removing 1 mg/min. If the blood concentration is 0.01 mg/mL (1 mg/dL), then one can say that 100 mL/min of blood is being "cleared" of creatinine, since, to get 1 mg of creatinine, 100 mL of blood containing 0.01 mg/mL would need to have been cleared. Creatinine clearance (CCr) is calculated from the creatinine concentration in the collected urine sample (UCr), urine flow rate (Vdt), and the plasma concentration (PCr). Since the product of urine concentration and urine flow rate yields creatinine excretion rate, which is the rate of removal from the blood, creatinine clearance is calculated as removal rate per min (UCr×Vdt) divided by the plasma creatinine concentration. This is commonly represented mathematically as
embassy vehicles and staff were no longer immune from penalties for traffic violations. American diplomats were asked to show work contracts for all domestic help (cooks, gardeners, drivers and security staff) employed within their households. Indian authorities also conducted an investigation into the American Embassy School. Nancy J. Powell, the U.S. ambassador to India, resigned following the incident, which was widely seen by India "as fallout from the imbroglio." Some commentators suggested that the incident and response could lead to wider damage in U.S.–India relations. Former Finance Minister Yashwant Sinha called for the arrest of same-sex companions of US diplomats, citing the Supreme Court of India's upholding of Section 377 of the Indian Penal Code whereby homosexuality is illegal in India. Former State Department legal advisor John Bellinger questioned whether the decision to arrest and detain Khobragade was "wise policy ... even if technically permissible" under the Vienna Convention on Consular Relations, while Robert D. Blackwill, the former U.S. ambassador to India from 2001 to 2003, said the incident was "stupid." Nevertheless, within a year of the incident, U.S.-India relations were warming again, as U.S. President Obama visited India in January 2015.
=== Forensic and archaeological === Blood residue can help forensic investigators identify weapons, reconstruct a criminal action, and link suspects to the crime. Through bloodstain pattern analysis, forensic information can also be gained from the spatial distribution of bloodstains. Blood residue analysis is also a technique used in archeology.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.